Literature DB >> 16105984

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Chiara Ambrogio1, Claudia Voena, Andrea D Manazza, Roberto Piva, Ludovica Riera, Laura Barberis, Carlotta Costa, Guido Tarone, Paola Defilippi, Emilio Hirsch, Elisabetta Boeri Erba, Shabaz Mohammed, Ole N Jensen, Giorgio Palestro, Giorgio Inghirami, Roberto Chiarle.   

Abstract

Translocations of the anaplastic lymphoma kinase (ALK) gene have been described in anaplastic large-cell lymphomas (ALCLs) and in stromal tumors. The most frequent translocation, t(2;5), generates the fusion protein nucleophosmin (NPM)-ALK with intrinsic tyrosine kinase activity. Along with transformation, NPM-ALK induces morphologic changes in fibroblasts and lymphoid cells, suggesting a direct role of ALK in cell shaping. In this study, we used a mass-spectrometry-based proteomic approach to search for proteins involved in cytoskeleton remodeling and identified p130Cas (p130 Crk-associated substrate) as a novel interactor of NPM-ALK. In 293 cells and in fibroblasts as well as in human ALK-positive lymphoma cell lines, NPM-ALK was able to bind p130Cas and to induce its phosphorylation. Both of the effects were dependent on ALK kinase activity and on the adaptor protein growth factor receptor-bound protein 2 (Grb2), since no binding or phosphorylation was found with the kinase-dead mutant NPM-ALK(K210R) or in the presence of a Grb2 dominant-negative protein. Phosphorylation of p130Cas by NPM-ALK was partially independent from Src (tyrosine kinase pp60c-src) kinase activity, as it was still detectable in Syf-/- cells. Finally, p130Cas-/- (also known as Bcar1-/-) fibroblasts expressing NPM-ALK showed impaired actin filament depolymerization and were no longer transformed compared with wild-type cells, indicating an essential role of p130Cas activation in ALK-mediated transformation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105984      PMCID: PMC1895100          DOI: 10.1182/blood-2005-03-1204

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Paxillin and focal adhesion signalling.

Authors:  C E Turner
Journal:  Nat Cell Biol       Date:  2000-12       Impact factor: 28.824

2.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.

Authors:  Z Ma; J Cools; P Marynen; X Cui; R Siebert; S Gesk; B Schlegelberger; B Peeters; C De Wolf-Peeters; I Wlodarska; S W Morris
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling.

Authors:  R L Rabin; M K Park; F Liao; R Swofford; D Stephany; J M Farber
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

4.  Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway.

Authors:  G A van Seventer; H J Salmen; S F Law; G M O'Neill; M M Mullen; A M Franz; S B Kanner; E A Golemis; J M van Seventer
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

5.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Authors:  Roberto Chiarle; Jerald Z Gong; Ilaria Guasparri; Anna Pesci; Jonjing Cai; Jian Liu; William J Simmons; Girish Dhall; Jennifer Howes; Roberto Piva; Giorgio Inghirami
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

6.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Authors:  R Y Bai; T Ouyang; C Miething; S W Morris; C Peschel; J Duyster
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

7.  Regulation of c-SRC activity and function by the adapter protein CAS.

Authors:  M R Burnham; P J Bruce-Staskal; M T Harte; C L Weidow; A Ma; S A Weed; A H Bouton
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway.

Authors:  B Souttou; N B Carvalho; D Raulais; M Vigny
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

9.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.

Authors:  A Slupianek; M Nieborowska-Skorska; G Hoser; A Morrione; M Majewski; L Xue; S W Morris; M A Wasik; T Skorski
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 10.  Paxillin interactions.

Authors:  C E Turner
Journal:  J Cell Sci       Date:  2000-12       Impact factor: 5.285

View more
  32 in total

1.  Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.

Authors:  Alpa M Nick; Rebecca L Stone; Guillermo Armaiz-Pena; Bulent Ozpolat; Ibrahim Tekedereli; Whitney S Graybill; Charles N Landen; Gabriel Villares; Pablo Vivas-Mejia; Justin Bottsford-Miller; Hye Sun Kim; Ju-Seog Lee; Soo Mi Kim; Keith A Baggerly; Prahlad T Ram; Michael T Deavers; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Natl Cancer Inst       Date:  2011-09-28       Impact factor: 13.506

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

5.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

6.  NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.

Authors:  C A Murga-Zamalloa; V Mendoza-Reinoso; A A Sahasrabuddhe; D Rolland; S R Hwang; S R P McDonnell; A P Sciallis; R A Wilcox; V Bashur; K Elenitoba-Johnson; M S Lim
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

7.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

8.  Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.

Authors:  Michael S Guerrero; J Thomas Parsons; Amy H Bouton
Journal:  Genes Cancer       Date:  2012-05

9.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Authors:  Chiara Ambrogio; Cinzia Martinengo; Claudia Voena; Fabrizio Tondat; Ludovica Riera; Paola Francia di Celle; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 10.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.